Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00583492 · ClinicalTrials.gov registry record · Phase 2
Randomized Trial of Suicide Gene Therapy and Prostate Cancer
A Phase 2 study, sponsored by Henry Ford Health System.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT00583492 is a Phase 2 study that has completed, run by Henry Ford Health System. The registered enrollment target is 44 participants.
The verdict
NCT00583492, a Phase 2 study, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
This is a randomized, controlled trial that will test the hypothesis that replication-competent adenovirus-mediated suicide gene therapy in combination with 80 Gy intensity modulated radiotherapy (IRMT)will improve freedom from failure (FFF) relative to 80 Gy IMRT alone in patients with newly-diagnosed prostate cancer with an intermediate-risk profile.
Interventions
- RADIATION IMRT
- BIOLOGICAL Ad5-yCD/mutTKSR39rep-ADP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2007-12 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00583492
The ClinicalTrials.gov registry entry for NCT00583492 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IMRT is the first listed.
NCT00583492 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00583492 about?
NCT00583492 is a clinical study titled "Randomized Trial of Suicide Gene Therapy and Prostate Cancer". This is a randomized, controlled trial that will test the hypothesis that replication-competent adenovirus-mediated suicide gene therapy in combination with 80 Gy intensity modulated radiotherapy (IRMT)will improve freedom from failure (FFF) relative to 80 Gy IMRT alone in patients with newly-diagno...
What is the current status of trial NCT00583492?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2007-12. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00583492?
The interventions under investigation include: IMRT (RADIATION), Ad5-yCD/mutTKSR39rep-ADP (BIOLOGICAL).
Who is sponsoring clinical trial NCT00583492?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.